The Long Road to Clinical Approval: From Weyburn to synthetic psilocybin

“Saskatchewan reports in the 1950s claimed roughly 50% recovery rates in treated alcoholics, without controls. The developer's application is targeted for Q4 2026. The interrupted clinical program is completing its interrupted work.”

When Osmond, Hoffer and colleagues reported their LSD alcoholism results in the late 1950s (for example Chwelos and colleagues, 1959), they presented a striking but uncontrolled finding: roughly half of treated alcoholic patients improved. The result exceeded anything available in 1961 psychiatry for alcohol use disorder. The finding did not lead to clinical approval, the Controlled Substances Act of 1970 ended the program.

The clinical research now reaching regulatory maturity uses psilocybin rather than LSD, structurally similar, pharmacologically analogous. A drug company's synthetic psilocybin has completed two Phase 3 trials: the first Phase 3 trial (June 2025) and the second Phase 3 trial (February 2026), both hitting primary endpoints for treatment-resistant depression. The NDA submission is targeted for Q4 2026, with potential FDA approval in late 2026 or early 2027.

FDA's Breakthrough Therapy Designation for synthetic psilocybin (2018) provides intensive FDA guidance and rolling review eligibility. The DEA increased its 2026 psilocybin production quota above the 2025 level, citing expanded research and clinical trial needs. The Usona Institute's IPR001 program, testing psilocybin for major depressive disorder, received a National Priority Voucher accelerating FDA review.

What approval means: synthetic psilocybin, if approved, would be the first FDA-approved psychedelic-assisted therapy. It would require certified clinical settings with trained therapists. The clinical model the FDA is approving is structurally what Osmond proposed in the 1950s: preparation, guided session, integration. The regulatory infrastructure for what Huxley called 'proper use' is, sixty-five years after the letters began, approaching completion.

Sources

• Hoffer & Osmond, J. Mental Sci. (1961) [Source not found; under review]
• Industry Phase 3 psilocybin trials (2025-2026)
• FDA Breakthrough Therapy Designation (2018)
• Online FDA approval tracker (April 2026)
• Chwelos, Blewett, Smith & Hoffer, Quarterly Journal of Studies on Alcohol (1959)